Kolltan Pharma raises $60 million to initiate Phase 1 trials for cancer growth blockers
Yale spin-off Kolltan Pharmaceuticals has raised $60 million to advance its cancer treatment through clinical trials, according to a Form D filing with the Securities and Exchange Commission. The drug developer sees potential for the drug across breast, lung and ovarian cancers. It also sees the drug as reducing the risk of patients showing resistance […]